


UK & Nordics: Life Sciences & Healthcare 1H 2025 Venture Financing

**United Kingdom & Nordics
Funding Focus 1H 2025**



Executive Summary

UK & Nordics Life Sciences & Healthcare 1H 2025

Mega Deal Mantras Dominating 1H 2025


Following a pivotal 2024, we've been monitoring 2025 with an eye to key themes supporting venture and scale in our life science markets. Themes such as reduced inflation, interest rate cuts, and an opening IPO window. The loudest signal to-date brings us to the art of the mega deal, where investors are moving on companies with strong management teams, differentiated technology, and of course artificial intelligence (AI).

Along with high-ticket fundraises, we've seen high quality investors at the forefront, placing headline grabbing big bets in select companies. We see this trend across geographies, and especially in our coverage markets for **UK and Nordics**.

- ◆ First Financing Activity – In a market buoyed by mega deal first financings such as Isomorphic Labs and Verdiva Bio, we see the rest of the market keeping relatively paltry pace. For example, we note just two (2) healthtech first financings in Q1, and just three (3) med device first financings in 1H 2025.
- ◆ BioPharma - In the 1H of 2025, the UK and Nordic biotech, dx/tools sector followed a similar pattern to 2024: total venture funding increased in the region despite a decline in transaction count, driven by a rise in average deal size. While the IPO market remained muted and broader venture activity pulled back amid geopolitical uncertainty and leadership transitions at the FDA, the period was buoyed by a mix of strong first financings early in Q1 and large mid-stage rounds later in the period Q2. Notably, several mega-rounds in biotech and techbio helped offset slower first financings and supported overall deal value growth.


- ◆ MedTech funding saw capital concentrated into fewer, high conviction, later stage deals, with mega-rounds for CMR Surgical and OrganOx dominating total capital raised.
- ◆ HealthTech data may reflect the 2024 mantra for, “cashflow breakeven”. The clearest trend reflects venture investing down nearly 50% year over year on both a volume and numerical basis, respectively.

Please reach out to us with your thoughts and for more details about our upcoming initiatives.



Michael White

UK & Nordics Market Manager,
Head of Life Sciences & Healthcare
Michael.White@hsbc.com



Dominick Kennerson

Director, Business Development
HealthTech, Life Sciences & Healthcare
Dominick.Kennerson@hsbc.com



Paula Burke

Director, HealthTech and Medical
Devices
Paula.burke@hsbc.com

Venture funding and average deal size trends

Mega-deals drive up the UK & Nordic equity pools

In the first half of 2025, both average deal size and total life science venture funding deployed in the UK and Nordics exceeded 2024 levels on an annualised basis.


Average deal size rose 53% year-over-year, while total venture deployment increased by 41%, driven primarily by the UK and its concentration of biotech and techbio mega-deals.

This surge in average deal size likely reflects a continued investor preference for selective, higher-quality opportunities in a market regaining its footing.

Although starting from a smaller base, the Nordics also benefited from the mega-deal trend but also saw increasing in transactions.

Total deal value climbed 69% year-over-year but also enjoyed increasing transactions 30% indicating a healthy ecosystem.



The Nordic VC Party: VC fundings up 69% in 1H 2025 led by healthtech unicorn & novel modality biotechs.



Most active investors by focus area

Venture investors, funds and corporates for UK + Nordics HQ companies






Biotech/Dx/Tools

| VC | Total Deal Count | First Financing Count (n) | Later Stage Count (n) | VC HQ |
|--|------------------|---------------------------|-----------------------|----------------------|
|  | 5 | 1 | 4 | Copenhagen, Denmark |
|  | 3 | 3 | 0 | Indiana, USA |
|  | 3 | 2 | 1 | Naarden, Netherlands |
|  | 3 | 2 | 1 | Stockholm, Sweden |
|  | 3 | 1 | 2 | Helsinki, Finland |
|  | 3 | 1 | 2 | Glasgow, Scotland |
|  | 3 | 4 | 4 | London, UK |

Med device

| VC | Total Deal Count | First Financing Count (n) | Later Stage Count (n) | VC HQ |
|---|------------------|---------------------------|-----------------------|---------------------|
|  | 3 | - | 3 | Manchester, UK |
|  | 2 | - | 2 | Wrexham, UK |
|  | 2 | - | 2 | Henley-in-Arden, UK |

Health tech

| VC | Total Deal Count | First Financing Count (n) | Later Stage Count (n) | VC HQ |
|---|------------------|---------------------------|-----------------------|-------------------|
|  | 2 | - | 2 | London, UK |
|  | 2 | 1 | 1 | Nordhavn, Denmark |
|  | 2 | 2 | - | Manchester, UK |
|  | 2 | - | 2 | London, UK |
|  | 2 | 2 | - | Berlin, Germany |

Biopharma, Dx/Tools

Early-stage venture investment activity
& value pools League table 1H 2025



Michael White

UK & Nordics Market Manager,
Head of Life Sciences & Healthcare

Michael.White@hsbc.com

Biopharma, Dx/Tools first-financing¹ largest financings

Novel modalities again lead top first financings in UK & Nordics; Neurodegenerative dominates 50% of Top 10; Strategic VC’s lead 6 of top 10 First Financing deals

Stage

70% of the companies in our Top 10 list are preclinical stage. As AI becomes increasingly embedded in the drug development process, several of these tech-biotechs will advance more rapidly into human trials than their non-AI peers. The largest round on the list, Isomorphic Labs, was founded by the impressive Nobel Laureate Demis Hassabis who cracked the decades old protein folding problem with AlphaFold at London’s DeepMind. We’re watching closely as he aims to challenge the traditional drug discovery model and rapidly enter the clinic at breakneck speed.

Geographic Trends

Five of the top 10 first financings in 1H 2025 were led by London or UK based companies, reflecting the Golden Triangle’s deep bench of academic research and proximity to specialist biotech investors. This geographic concentration underscores London/UK’s growing role as a hub for early-stage biotech innovation in Europe.

Investors











In addition to repeat participation from top European VCs like Forbion, Novo, and SV Health, we observed a notable surge in corporate and strategic investor involvement; rising from 30% of first financings in 2024 to 60% in 1H 2025. With the looming patent cliff, future revenue growth, and attractive valuation arbitrage in the UK and Europe, Big Pharma and Big Tech are leaning in. Perhaps most emblematic of this trend is Isomorphic Labs, backed by Google *and* Alphabet.

Novel modalities and Untapped Disease Areas

As in 2024, the largest first financings in the UK and Nordics centered on novel modalities and untapped disease areas. Where oncology small molecules once dominated, today’s biotech frontier is defined by next-generation oral GLP-1s, molecular degraders, bispecific complement engagers (BiCEs), and other platform-based innovations. With the oncology standard of care evolving, investor and scientific focus is increasingly shifting toward obesity, neurodegeneration, and more complex autoimmune disease categories. One example of this, ViceBio, backed by Medicxi, UniQuest, and Avoro, leveraged its novel molecular clamp technology to help drive Sanofi’s recent \$1.15B acquisition of the London-based biotech.

Vicebio, leveraged its novel molecular clamp technology to drive Sanofi’s recent \$1.15B acquisition of the London based biotech.



| # | Company | Indication Stage | Size of Round | Lead Investor | Location |
|----|---|-----------------------------|---------------|--|---------------------|
| 1 |  Isomorphic Labs | Platform | £446M | Thrive Capital, GV, Alphabet | London, UK |
| 2 |  Verdiva Bio | Metabolic/Obesity Ph2 | £316M | General Atlantic Forbion, Orbimed, RA | Guildford, UK |
| 3 |  Draig Therapeutics | Neuro, Ph2 | £90.5M | Access Industries, Sanofi, SV, SROne, Canaan | Cardiff, UK |
| 4 |  Tribune Therapeutics | Fibrosis, Pre-clinical | £31M | LifeArc Ventures, Novo Holdings | Stockholm, Sweden |
| 5 |  TRIMTECH THERAPEUTICS | Neuro, Pre-clinical | £25M | Cambridge Innovation, Pfizer, M SV Health | Cambridge, UK |
| 6 |  Arctic Therapeutics | Neuro, Alzheimer’s, Ph2 | £21M | Sanos Group 21 Impact Labs | Reykjavik, Iceland |
| 7 |  Commit Biologics | BiCE, Pre-clinical | £17M | Novo Holdings Bioqube Ventures | Aarhus, Denmark |
| 8 |  NEUMiRNA Therapeutics | Neuro, Pre-clinical | £16M | Angelini Ventures Invivo Partners | Copenhagen, Denmark |
| 9 |  Cephagenix | Neuro/Migraine Pre-clinical | £7M | AbbVie Ventures AdBio | Glostrup, Denmark |
| 10 |  LARIO | Neuro/Epilepsy Pre-clinical | £6M | * | Edinburgh, UK |

Biopharma, Dx/Tools first-financing¹ by indication

Metabolic and Neurodegenerative Steal the Show


Platform grows while Oncology slows but Metabolic and Neurodegenerative dominate first financing stage

While platform financing in 1H 2025 was dominated by a single mega-deal; Isomorphic Labs accounting for £446M of the £474M total - the more telling story may be the dramatic drop in oncology first financings, down 90% from 2024. Echoing trends from our global report, investor caution in oncology was fueled by uncertainty around tariffs, NIH funding, and leadership changes at the FDA, leading many to pause on early-stage bets in the space.

In contrast, investor enthusiasm surged in two key areas: neurodegeneration and metabolic/obesity. Compared to the same period in 2024, first financing in metabolic indications rose 821% (8x), while neurodegenerative deals jumped 783% (8x); both a striking pivot in capital allocation.

Two standout neuro deals—Draig Therapeutics (UK) and Trimtech (UK) were both backed by strong, balanced syndicates featuring SV Health in both deals. SV’s involvement underscores a growing commitment to the firm’s Dementia Discovery Fund, which is laser-focused on advancing novel therapeutics for patients suffering from dementia. With macro patient trends aligning in neuro, concentrated regional investment in the space, and the recent close of its second fund \$229M DDF-2, SV Health appears to be a visionary leader in focused neurodegenerative investing.

SV Health’s Dementia Discovery Fund blazes a trail in disciplined & focused neuro investing.



Biopharma, Dx/Tools largest financings (all deals)

The region again forms a barbell effect with the vast majority of deals either very early or very late – why?

Numbers at a Glance: Trend Analysis Top 20 Biotech & Dx/Tools Largest Deals

Stage Focus: “Barbell” Investment Strategy in 1H 2025











Early-stage biotech dominated the largest financings in 1H 2025, with eight of the top 20 deals involving preclinical companies and another seven in Phase 2. This “barbell” trend—concentrated investment at both the early and late ends of the development spectrum—is consistent with our HSBC global data and suggests that investors are willing to write large checks for biotech companies pursuing innovative modalities and targeting high unmet needs with large or well reimbursed (ie rare disease) patient populations.

At the early stage, we continue to see a pattern of overfunding preclinical biotechs—a strategy that appears designed to de-risk financing needs for the next 2–3 years. This reflects investor conviction in select platforms and has been an emerging phenomenon since last year’s report, now reaffirmed in this cycle.

Conversely, the concentration of large biotech VC financings at the later stage, Phase 2, reflect a different thesis. With the IPO window still largely closed or seen as merely a financing event and not an exit, investors are backing later-stage companies they believe can quickly reach registration and book revenue at a strong YoY growth rate and become attractive acquisition targets of Big Pharma needing to replace patent cliff product sales. This is supported by a string of landmark biotech exits in 2025, including J&J’s \$14.6B acquisition of Intercellular, Sanofi’s \$9.5B buyout of Blueprint Medicines, and Merck’s \$10B acquisition of Verona. Each of these commercial stage assets were outperforming sales expectations (50%+), at scale, and were acquired at a substantial premium, reinforcing the view that Phase 2-stage companies with clear paths to commercialization represent one of the few viable near-term liquidity opportunities for biotech specialist investors.

Biotech M&A rarely crosses the \$10B level - but 2025 is breaking the mold: Newly approved drugs with scale and +50% revenue growth, is proving to be the golden ticket to \$10B exit for investors.



| # | Company | Indication Stage | Size of Round | Lead Investor | Location |
|----|---|------------------------|----------------|--|-------------------------|
| 1 |  Isomorphic Labs | Platform | £446M | Thrive Capital, GV, Alphabet | London, UK |
| 2 |  Verdiva Bio | Metabolic/Obesity Ph2 | £316M | General Atlantic, Forbion, Orbimed, RA | Guildford, UK |
| 3 |  CellCentric | Oncology, Ph2 | £92M, Series c | Avego Management, Forbion | Cambridge, UK |
| 4 |  Draig Therapeutics | Neuro, Ph2 | £90.5M | Access Industries, Sanofi, SV, SROne, Canaan | Cardiff, UK |
| 5 |  crbis MEDICINES | Platform Pre-Clinical | £73M, Series A | Forbion, Novo Holdings | Fredericksburg, Denmark |
| 6 |  maxion therapeutics | Platform Pre-Clinical | £55M, Series A | British Patient Capital, General Catalyst, Eli Lilly | Cambridge, UK |
| 7 |  Latent Labs | Dx/Tool Computational | £31M, Series A | Sofinnova | London, UK |
| 8 |  Tribune Therapeutics | Fibrosis, Pre-clinical | £31M | LifeArc Ventures, Novo Holdings | Stockholm, Sweden |
| 9 |  Portal | Dx/Tool Single Cell | £27M, Series A | NATO Innovation Fund | Copenhagen, Denmark |
| 10 |  TRIMTECH THERAPEUTICS | Neuro, Pre-clinical | £25M | Cambridge Innovation, Pfizer, M, SV Health | Cambridge, UK |

Biopharma, Dx/Tools largest financings (all deals)

Well regarded investors from UK, Europe, and US support most innovative companies with strategics and non-profits joining large syndicates.

Investor Trends: Forbion Stands Out in 1H 2025

The top 20 largest financings in 1H 2025 featured many of the usual heavyweights—Novo Holdings, RA Capital, OrbiMed, General Atlantic, General Catalyst, and Sofinnova—as well as a notable presence of strategic investors and non-profits.









However, one investor stood out for its consistent presence and conviction: Forbion. Following its new €2 billion fundraise in late 2024, the Amsterdam-based firm emerged as a dominant force in the region, backing three of the top five financings in the UK and Nordics in 1H 2025.

Autoimmune Momentum Emerges in Europe

Two autoimmune-focused companies—Tribune Therapeutics and Commit Biologics—entered the year’s top financings in 2025, both backed by Novo Holdings. This marks a sharp shift from 2024, when no such companies secured meaningful funding. The renewed interest draws tailwinds from the Abivax story: the Paris-based, VC and venture debt funded biotech, in Phase 3 trials, posted positive ulcerative colitis data, driving a 700% share price surge and a \$747 million follow-on equity raise. This milestone underscored the value late-stage data can create and appears to have prompted UK and European investors to reappraise autoimmune—a long established trend in the US.

Abivax, a Phase 3 biotech, funded with VC equity and **venture debt** based in Paris, has put automimmune back on the map for European investors after a 700% stock pop and raising \$747 million on its Ph3 autoimmune data in 2025.



| # | Company | Indication Stage | Size of Round | Lead Investor | Location |
|----|--|-------------------------|----------------|---|---------------------|
| 1 |  Beckley Psytech | Neuro Ph2 | £23M | Ferring Ventures | Oslo, Norway |
| 2 |  Dowlstone Medical | Dx/Tools Dx Test | £23M, Series E | Ventura Capital, Cystic Fibrosis Foundation | Cambridge, UK |
| 3 |  Arctic Therapeutics | Neuro, Alzheimer’s, Ph2 | £21M Series A | Sanos Group 21 Impact Labs | Reykjavik, Iceland |
| 4 |  GESYNTA PHARMA AB | Neuro Ph2 | £21M, Series B | Amboy Street Ventures | Stockholm, Sweden |
| 5 |  tilt BIOTHERAPEUTICS | Oncology Ph 1/2 | £19M, Series B | * | Helsinki, Finland |
| 6 |  Commit Biologics | BiCE, Pre-clinical | £17M | Novo Holdings Bioqube Ventures | Aarhus, Denmark |
| 7 |  NEUmiRNA Therapeutics | Neuro, Pre-clinical | £16M | Angelini Ventures Invivo Partners | Copenhagen, Denmark |
| 8 |  VALOTx | Oncology Ph2 | £15M | CDP Venture Capital | Helsinki, Finland |
| 9 |  BRAINOMIX | Platform | £13M Series C | LifeSci Venture Partners | Oxford, UK |
| 10 |  enso cell therapeutics | Dx/Tools R&D Tool | £10M | * | Cambridge, UK |

Med Device

Early-stage venture investment activity
& value pools League table 1H 2025






Paula Burke

Director, Digital Health & Devices

Paula.Burke@hsbc.com

UK & Nordics Med Device Notable Financings 1H 2025

Top 10 League Table for 1H 2025 MedTech Venture Financing

| # | Company | MedTech Subsector | Round Size £M ¹ | Round Label | Lead Investor | Company HQ |
|----|---|--|----------------------------|-------------|--|----------------------|
| 1 |  OrganOx living organs for life | Surgical: Organ transplantation | 121.4 | - | HealthQuest Capital | Oxford, UK |
| 2 |  CMR SURGICAL | Surgical: Robotics | 100.1 | Series D2 | Ally Bridge; Softbank | Cambridge, UK |
| 3 |  CARDIOMECH | Cardiovascular: Structural heart | 13.5 | - | Undisclosed | Trondheim, Norway |
| 4 |  CIPHER SURGICAL | Surgical: Endoscopic vision | 7.7 | Series A | Medical Solutions (MSI) | Coventry, UK |
| 5 |  AXIS SPINE TECHNOLOGIES | Orthopaedic: Spine | 6.7 | - | Mercia Ventures; Northern Venture Trust | Saint Albans, UK |
| 6 |  SURGIFY FOR SAFER BONE SURGERY | Surgical: Bone | 5.9 | Series A | ZEISS Ventures | Espoo, Finland |
| 7 |  Ceryx Medical | Cardiovascular: Implantable bioelectronics | 5.0 | - | Parkwalk Advisors; Development Bank of Wales | Cardiff, UK |
| 8 |  osaa INNOVATION | Surgical: IV therapy | 4.6 | Seed | Undisclosed | Ballerup, Denmark |
| 9 |  eventum orthopaedics | Orthopaedic: Knee | 3.8 | - | Mercia Ventures; NPIF | Leeds, UK |
| 10 |  Samphire | NIM: Neuro / female health | 3.7 | Seed | Inventure VC | London, UK |

¹Exchange rate as of date of financing

UK & Nordics 1H 2025 Top 10 Fundraising Rounds

- Medical device funding in the UK and Nordics for 1H 2025 exceeded the total raised in all of 2023 and is tracking slightly ahead of 1H 2024. This growth came despite deal volumes falling by almost half year-on-year, reflecting a more selective investment environment.
- Funding was highly concentrated, with a median deal size across the top 10 funding rounds of ~£6.2m. This was driven largely by two UK mega-rounds for CMR Surgical (surgical robotics) and OrganOx (organ preservation). Both companies operate in high-value procedural markets and have strong platform technologies capable of dominating global categories. The size and stage of these raises reflects the broader global pivot away from early-stage bets towards later stage, de-risked assets with clear clinical (and in this case commercial) traction. This is further underscored with first financings representing less than a fifth of deals and just 5% of total funding.
- In the absence of open IPO markets for most MedTech categories, these large conviction led rounds balance runway extension and strategic optionality, with investors concentrating capital in companies with credible pathways to exit.
- Surgical and cardiovascular deals dominated the top 10 financings, consistent with their large market opportunities and strong acquisition interest. Orthopaedics saw a respectable number of deals in relation to the top 10 financings but at smaller ticket sizes, reflecting lower capital requirements and different regulatory and commercial pathways.
- Notably, Samphire Neuroscience seed round featured amongst the top 10 but came in below the median deal size, highlighting both the underfunded nature of women's health devices and the early-stage focus of the sector. Nevertheless, its inclusion signals growing investor interest in female focused therapeutic areas and their connection to brain health, which remain nascent but present long-term growth opportunities.

Healthtech

Early-stage venture investment activity
& value pools League table 1H 2025



Dominick Kennerson

Director, Business Development
HealthTech, Life Sciences &
Healthcare

Dominick.Kennerson@hsbc.com

Early stage healthtech venture investment activity

Healthtech first financing trends

First-financings represent a key performance indicator for a thriving venture ecosystem. For the UK especially, the country’s support for Venture Capital Trusts (VCTs) and Enterprise Investment Scheme (EIS) funding creates the opportunity for upside amongst a broad investment and government tax-supported funding regime.


While megarounds dominate headlines, UK/Nordic first financings seem to demonstrate a market with developing potential, evidenced **at the top by Evaro**. Unlike the United States, a nation largely led in healthtech funding by provider operations companies, we see UK/Nordic first financing with **alternative care** and **medication management**, with alternative care riding its **2024 momentum**. With NHS changes, and new healthcare initiatives underway across UK government, we expect that the provider operation trend may take a bit longer to develop in the UK.

Interestingly, while AI companies in healthcare may seem to be dominating headlines, this cohort seems to focus its technology approach from a platform or module view, aggregating providers and patients for less healthcare friction. For example (and simply stated), **Evaro** and **Healthera** are platforms designed for pharmacist and/or patient, enhancing access and experience. While **Careloop** does mention a predictive algorithm feature, **XARlabs** seems to focus on its AI position more than others in this cohort.

As aggregator platforms with interfaces with patient and/or provider, these businesses also prominently feature customer reviews, via Trustpilot, Google, or some other platform. As such, given the scale of reviews, one may consider that these healthtech companies have generated significant sales, prior to the funding round, potentially generating significant revenues, and potentially optimizing for CAC metrics for sales efficiency.

- 2023 n = 26 early stage healthtech investments
- 2024 n = 13 early stage healthtech investments
- 1H 2025 n = 9 early stage healthtech investments**

On a frequency basis, 1H 2025 healthtech first financing investing is ahead of 2024’s pace, but a bit behind what was considered a soft year in 2023.



| | | |
|------------------------|---|---|
| HealthTech Value Pools | Medication Management 2 COMPANIES £ 24.5M TOTAL RAISED | Alternative Care 2 COMPANIES £ 9.3M TOTAL RAISED |
| | Provider Ops 2 COMPANIES £ 2.9M TOTAL RAISED | Healthcare Navigation £ 2.2M TOTAL RAISED |
| | Wellness & Education £ 1.9M TOTAL RAISED | Clinical Trials £ 3.2M TOTAL RAISED |

UK & Nordics HealthTech Notable Financings 1H 2025

Top 10 League Table for 1H 2025 HealthTech Venture Financing

| # | Company | MedTech Subsector | Round Size £M ¹ | Round Label | Lead Investor | Company HQ |
|----|--|---|----------------------------|-------------|--------------------------|-------------------|
| 1 |  NEKO | Wellness & Education: Education & Wellness | 202 | Series B | Lightspeed | Stockholm, Sweden |
| 2 |  Cera+ | Alternative Care: Primary Care | 116 | Series C1 | BDT MSD Partners | London, UK |
| 3 |  LindusHealth | Clinical Trials: Clinical Trial Enablement | 42.7 | Series B | Balderton | London, UK |
| 4 |  Tandem | Provider Operations: Workflow | 38.9 | Series A | Kinnevik | Stockholm, Sweden |
| 5 |  lottie | Healthcare Navigation: Provider Matching | 24 | Series B | * | London, UK |
| 6 |  elvie | Alternative Care: Women's Health | 21.8 | Series C | Blume Equity | London, UK |
| 7 |  evaro | Medication Management: Medication Delivery | 20 | - | AlbionVC, Guinness | Norwich, UK |
| 8 |  skin analytics | Provider Operations: Clinical Decision Support | 15 | Series B | Intrepid Growth Partners | Cambridge, UK |
| 9 |  DENTME | Healthcare Navigation: Provider Matching | 12 | - | NCPA Capital | Stockholm, Sweden |
| 10 |  Gaia | Healthcare Navigation: Payer Matching | 11.7 | - | Collective Ventures | London, UK |

UK & Nordics 1H 2025 Top 10 Fundraising Rounds

- ◆ The 1H 2025 story thus far, is the return of the healthtech IPO, with successful market debuts from both Hinge Health Inc. (**NYSE: HNGE**) and Omada Health Inc. (**NASD: OMDA**). While Omada, in its virtual care cardio-metabolic business may be positioned to ride the GLP-1 wave, Hinge is known for building its success on hockey stick style “**calculated billings growth**” (LTM calculated billings defined as total revenue, plus the change in deferred revenue, less the change in contract assets for a given 12-month period). Notably, we’re also keeping an eye to the markets to also monitor the S-1 filing for Heartflow’s (**NASD: HTFL**) planned IPO.
- ◆ In our [UK & Nordics: Life sciences & healthcare 2024 venture financing report](#), we discuss the bifurcation in healthtech fundraising, a trend we’ve seen largely continue into 2025. While the top of the market is commanded by large fundraising rounds with marquee investors, there seems to be just a trickle of steady, high quality venture deals. One indicator may be the spread between the average deal size contrasted to the median deal size:
 - ◆ For our UK top 10 healthtech, the average deal size is £51M.
 - ◆ For our UK top 10 healthtech, **the median deal size is £23M**, which as a measure of central tendency in this market may be a more reliable market sizing metric.
- ◆ While much of the U.S. healthtech mega deal trend is centered around provider operations, ambient AI platforms, we have yet to see such a strong trend develop on this side of the Atlantic.

Healthcare Perspectives


UK and Nordics Life Sciences & Healthcare 1H 2025 and 2H 2025/2026 Outlook



Biotech, Diagnostics/Tools

The first half of 2025 saw strong total venture funding in the UK and Nordics, buoyed by Q1 momentum, high-value mid-stage rounds, and mega-deals in techbio. Despite weak first financing activity in Q2, the IPO market remained muted, oncology financings slowed sharply, and M&A in late-stage assets continued to deliver substantial premiums, sustaining investor confidence.

Looking ahead, we expect first financings to return to Q1 levels as geopolitical conditions and FDA leadership stabilize, steady M&A activity to continue providing liquidity, and a gradual reopening of the IPO window in 2026. This should help specialist funds raise new capital and support early-stage financings especially in the UK's Golden Triangle. We also anticipate more large-scale techbio raises, increased early-stage neurodegenerative financings, and growing autoimmune activity, as the Abivax success story encourages UK and Nordic investors to follow this well-established US trend in autoimmune.



Med Device

Despite heightened uncertainty around tariffs, changes to FDA staffing and broader macroeconomic pressures, MedTech investment reached a three year high in the first half of 2025.

However, deal volume fell sharply, and capital was highly concentrated, with most funding flowing into a small number of later stage, high-conviction transactions, underscoring a market that is more selective. Two UK mega-rounds set the tone, reflecting investor preference for high-value procedural markets capable of dominating global categories.

Looking ahead we anticipate MedTech for the region to continue to “build local, scale global”, leveraging R&D and early clinical development in the UK and Nordic regions while prioritising scale up in the USA and other high-revenue markets. We expect total investment to continue at a steady pace but late-stage concentration and secondaries to persist until public markets reopen in a meaningful way. In 2026, AI integration will likely play a more central role in select medical devices enhancing precision, automation and competitive edge.



HealthTech

The UK & Nordics healthtech market suggests a “quality vs. quantity” dynamic where investors are carefully considering opportunities with scale, revenue, and reliable metrics. Seemingly on the sidelines remain companies, which have been fundraising for some time on the “cashflow breakeven” mantra.

On a technology basis, while the AI-hype cycle builds, UK & Nordic healthtech is seemingly taking a more pragmatic approach to clarify AI as a feature, and/or hidden backbone-engine, but relying on experience as a key differentiator in a market often characterized by healthcare friction points.

As healthtech's north star, the US value generation in the first half, including the IPO window, coupled with significant fundraising rounds do give life to valuations everywhere.

Life Sciences and Healthcare Relationship Team

A dedicated team of sector and investor access experts ready to connect you to whatever's next, now



Helena Fraser
Vice President –
Biopharma, Diagnostics
& Tools



Jamie Bignal
Director - Biopharma,
Diagnostics & Tools



Sebastian Penn
Head of Nordics



Maria Ljungberg
Director, Sweden



Maria Bo
Director, Denmark



Stephen Lowery
Head of Investor
Coverage & Business
Development



Tom Butterworth
Director,
Investor Coverage &
Business Development



Richard Faulkner
Managing Director,
Investor Coverage &
Business Development



Jonno Southam
Managing Director,
Investor Success

Thank you

This material including, without limitation, the statistical information herein, is provided for informational purposes only. The material is based in part on information from third-party sources that we believe to be reliable but which have not been independently verified by us, and for this reason, we do not represent that the information is accurate or complete. The information should not be viewed as tax, investment, legal or other advice, nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision. Nothing relating to the material should be construed as a solicitation, offer or recommendation to acquire or dispose of any investment or to engage in any other transaction

© 2025 HSBC Innovation Bank Limited. All rights reserved. HSBC Innovation Bank Limited (trading as HSBC Innovation Banking) is registered in England and Wales at Alphabeta, 14-18 Finsbury Square, London EC2A 1BR, UK (Company Number 12546585). HSBC Innovation Bank Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and Prudential Regulation Authority (Firm Reference Number 543146). HSBC Innovation Bank Limited is part of the HSBC Group. HSBC Innovation Bank Limited is committed to making its website and related documents accessible to everyone. Learn more on www.hsbcinnovationbanking.com/accessibility